Related Experiment Video

Updated: Jun 4, 2026

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

Survivin isoform expression patterns in CML patients correlate with resistance to imatinib and progression, but do

Matthaios Speletas1, Nikoletta Argentou, Vaios Karanikas

  • 1Department of Immunology & Histocompatibitity, University of Thessaly, Medical School, 41110 Biopolis, Larissa, Greece. maspel@med.uth.gr

Clinical Immunology (Orlando, Fla.)
|February 24, 2011
PubMed

Insights

Novel immunotherapy targeting survivin in chronic myeloid leukemia (CML) may not be effective. Standard survivin levels impact imatinib response, while anti-survivin T cells are absent, questioning therapeutic validity.

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • Tyrosine-kinase inhibitors (TKIs) are effective for chronic myeloid leukemia (CML) but relapse is common.
  • Novel therapeutic strategies, including anti-survivin treatments, are being explored for CML.
  • Survivin isoforms and CD8(+) T cell responses are implicated in cancer progression and treatment resistance.

Purpose of the Study:

  • To investigate the expression of survivin isoforms in CML patients.
  • To assess the role of CD8(+) T cells in anti-survivin immunotherapy for CML.
  • To correlate survivin expression with CML stage and response to imatinib therapy.

Main Methods:

  • Analysis of survivin isoform expression (standard, survivin-2B, -ΔEx3) in 51 CML patients.
  • Evaluation of CD8(+) T cells targeting survivin.
  • Correlation of survivin levels with CML stage and imatinib response.

Main Results:

  • Advanced-stage CML patients showed increased standard survivin and decreased survivin-2B/-ΔEx3.
  • Higher standard survivin expression correlated with a 3.5-fold increased risk of suboptimal imatinib response in chronic phase CML.
  • Responders exhibited significant upregulation of all survivin isoforms in bone marrow.
  • Anti-survivin CD8(+) T cells were undetectable in all patients.

Conclusions:

  • Survivin isoform expression patterns are associated with CML progression and TKI treatment outcomes.
  • The absence of detectable anti-survivin CD8(+) T cells challenges the efficacy of survivin-targeted immunotherapy in CML.
  • Further research is needed to explore alternative therapeutic strategies for CML management.

More Related Videos

Ex Vivo Culture of Circulating Tumor Cells in the Cerebral Spinal Fluid from Melanoma Patients to Study Melanoma-Associated Leptomeningeal Disease06:25

Ex Vivo Culture of Circulating Tumor Cells in the Cerebral Spinal Fluid from Melanoma Patients to Study Melanoma-Associated Leptomeningeal Disease

Published on: March 29, 2024

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...